Mandate

Vinge advises FSN Capital and Seriline in connection with the add-on acquisition of Areff Systems

Vinge advises FSN Capital and Seriline in connection with the acquisition of Areff Systems AB from its founders. The founders remain in the merged company and has reinvested a significant proportion of the purchase price in the group.

At the end of February 2022, the private equity firm FSN Capital acquired a majority stake in Seriline with the ambition of consolidating the market for physical and digital identity and access control. The acquisition of Seriline is now followed up with the acquisition of Areff Systems, where FSN Capital accounts for a majority of the financing. Areff Systems works with security and identification solutions and currently has 18 employees. The acquisition of Areff Systems will increase Seriline’s turnover with almost 50 percent to around SEK 150 million for 2022.

Vinge’s team mainly consisted of Johan Winnerblad, Maria Dahlin Kolvik, Eléonore Friberg and Ebba Nyberg (M&A), Mathilda Persson (IT), Sara Strandberg (Employment) and Axel Lennartsson (IPR).

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025